Search hospitals > Connecticut > New Haven
Yale University School of Medicine
Claim this profileNew Haven, Connecticut 06510
Global Leader in Alzheimer's Disease
Global Leader in Type 1 Diabetes
Conducts research for Diabetes
Conducts research for Obesity
Conducts research for Skin Cancer
728 reported clinical trials
61 medical researchers
Summary
Yale University School of Medicine is a medical facility located in New Haven, Connecticut. This center is recognized for care of Alzheimer's Disease, Type 1 Diabetes, Diabetes, Obesity, Skin Cancer and other specialties. Yale University School of Medicine is involved with conducting 728 clinical trials across 747 conditions. There are 61 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Charles Matouk.Area of expertise
1Alzheimer's Disease
Global LeaderPSEN2 positive
PSEN1 positive
APP positive
2Type 1 Diabetes
Global LeadermIAA positive
IA-2A positive
ZnT8A positive
Top PIs
Patricia M LorussoYale Cancer Center6 years of reported clinical research
Expert in Solid Tumors
Expert in Uterine Tumors
27 reported clinical trials
43 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
17 reported clinical trials
25 drugs studied
Amer M. ZeidanYale Cancer Center4 years of reported clinical research
Expert in Myelodysplastic Syndrome
Expert in T-Lymphoblastic Leukemia/Lymphoma
17 reported clinical trials
27 drugs studied
Charles MatoukYale University6 years of reported clinical research
Studies Stroke
Studies Intracranial Aneurysms
12 reported clinical trials
11 drugs studied
Clinical Trials running at Yale University School of Medicine
Multiple Myeloma
Ovarian Cancer
Colorectal Cancer
Prostate Cancer
Lymphoma
Lupus
Endometrial Cancer
Uterine Tumors
Solid Tumors
Non-Hodgkin's Lymphoma
Ide-cel + Lenalidomide
for Multiple Myeloma
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Recruiting2 awards Phase 31 criteria
Mezigdomide Combo vs. Pomalidomide Combo
for Multiple Myeloma
This trial is testing two drug combinations to find out which one is better and safer for patients with multiple myeloma that has come back or not responded to previous treatments. The drugs work together to kill cancer cells by stopping their growth, helping the immune system attack them, and making it harder for them to survive.
Recruiting2 awards Phase 3
Talquetamab Combinations
for Multiple Myeloma
This trial is testing two new drug combinations to treat multiple myeloma. The combinations include talquetamab with either pomalidomide or teclistamab. These drugs help the immune system better identify and destroy cancer cells. The goal is to see if these new combinations work better than existing treatments.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Yale University School of Medicine?
Where is Yale University School of Medicine located?
Who should I call to ask about financial aid or insurance network?
What insurance does Yale University School of Medicine accept?
What awards or recognition has Yale University School of Medicine received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.